## ADPT: Adaptive Biotechnologies Corpor - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.3% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($13.43)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Adaptive (NASDAQ: ADPT) signs RA TCR, data licensing pacts with Pfizer (NYSE: PFE)**
- Source: Stock Titan | 20251215T130845 | Bullish | Relevance: 100%
- Adaptive Biotechnologies announced two non-exclusive agreements with Pfizer: a target discovery collaboration for rheumatoid arthritis (RA) T-cell receptors and a data licensing deal for Adaptive's TCR-antigen datasets. Adaptive could receive an upfront payment and up to $890 million in potential milestones for the RA agreement, with Pfizer handling development and commercialization. These agreements leverage Adaptive's immune medicine platform and large datasets to accelerate drug discovery in immunology.

**2. Adaptive Biotechnologies stock rises after Pfizer deals worth up to $890M**
- Source: Investing.com | 20251215T160845 | Bullish | Relevance: 100%
- Adaptive Biotechnologies (NASDAQ:ADPT) stock increased by 4.3% in premarket trading after announcing two non-exclusive agreements with Pfizer (NYSE:PFE) potentially worth up to $890 million. These deals include a target discovery agreement for rheumatoid arthritis and a data licensing agreement for Pfizer to access Adaptiveâ€™s proprietary TCR-antigen datasets for immunology research. Adaptive will receive an upfront payment and could be eligible for significant additional payments based on milestones.

**3. Adaptive Biotechnologies inks two agreements with Pfizer in immunology**
- Source: Investing.com | 20251215T160845 | Bullish | Relevance: 100%
- Adaptive Biotechnologies has signed two non-exclusive agreements with Pfizer focusing on T-cell receptor (TCR) discovery and immune data licensing. One agreement involves identifying disease-causing TCRs for rheumatoid arthritis, potentially yielding up to $890 million in milestone payments. The second grants Pfizer access to Adaptive's TCR-antigen datasets to develop AI and machine learning models for research.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($1.20M) |
| Sells | 11 ($5.58M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Viking Global Invest: 19.7% (0.0%)
- Blackrock Inc.: 8.8% (-2.3%)
- Vanguard Group Inc: 7.4% (-0.0%)
- Ameriprise Financial: 3.9% (+84.3%)
- Sumitomo Mitsui Trus: 2.4% (-15.1%)

### Key Risks

1. High beta (2.20) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Insider selling cluster: $5.6M in recent transactions.
3. Elevated short interest (8.7%): bears positioning against stock.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.57 indicates undervaluation relative to growth. Balance sheet: strong liquidity (3.4x). Insider selling cluster ($5.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.4B |
| Beta | 2.20 |
| 52W Range | $5.80 - $20.76 |
| Short Interest | 8.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.57 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from -16.5% to -0.3% (+16.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.3pp (needs >3.0% for momentum thesis). MRS_5 turning positive (3.2%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.32x) but short-term weakness (below SMA20). RSI neutral at 46. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.33% (CS: 24) | Neutral |
| RSI_14 | 46.0 | Neutral |
| MACD Histogram | -0.31 | Bearish |
| vs SMA20 | 0.932x | Below |
| vs SMA50 | 0.958x | Below |
| vs SMA200 | 1.325x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $15.69
- **Stop Loss:** $13.43 (14.4% risk)
- **Target:** $17.95 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 530
- **Position Value:** $8,315.70
- **Portfolio %:** 8.32%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-10 (Est: $-0.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.14 | $0.06 | +143.3% |
| 2025Q2 | $-0.24 | $-0.17 | +28.6% |
| 2025Q1 | $-0.31 | $-0.20 | +35.5% |
| 2024Q4 | $-0.24 | $-0.23 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*